Company intelligence / Profile preview
Frontera Therapeutics
Shanghai, Shanghai, Chinafronteratherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Frontera has advanced multiple rAAV-based gene therapies into clinical development. Four ophthalmology programs have entered or completed Phase II trials with "Best-in-Class" potential. FT‑003 demonstrated strong efficacy and safety in nAMD/DME patients (>20 followed up to two years), while FT‑002 showed significant improvements in retinal sensitivity and BCVA for XLRP. The company’s robust platform enables rapid progression of candidates into the clinic[3][8][9].
- Therapeutic areas
- CardiovascularOphthalmologyHematology
- Modalities
- Gene therapyRecombinant adeno-associated virus (rAAV) gene therapyBiologic (via rAAV vectors)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
No major disclosed pharma partnerships as of June 2025
Beyond the preview
Go deeper on Frontera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Frontera Therapeutics.